A citation-based method for searching scientific literature

Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer.
Feiyue Zheng, Yi Zhang, Shuang Chen, Xiang Weng, Yuefeng Rao, Hongmei Fang. Biomed Pharmacother 2020
Times Cited: 27



Integrated genomic analyses of ovarian carcinoma.
. Nature 2011
Times Cited: 4816




List of shared articles



Times cited

Research progress on the association between environmental pollutants and the resistance mechanism of PARP inhibitors in ovarian cancer.
Lina Zhou, Jiangdong Xiang, Yinyan He. Environ Sci Pollut Res Int 2021
0

Specific Mechanisms of Chromosomal Instability Indicate Therapeutic Sensitivities in High-Grade Serous Ovarian Carcinoma.
Naoka Tamura, Nadeem Shaikh, Daniel Muliaditan, Tanya N Soliman, Jennifer R McGuinness, Eleni Maniati, Daniela Moralli, Mary-Anne Durin, Catherine M Green, Frances R Balkwill,[...]. Cancer Res 2020
11

Combination effect of poly (ADP-ribose) polymerase inhibitor and DNA demethylating agents for treatment of epithelial ovarian cancer.
Jung-In Shim, Ji-Yoon Ryu, Soo Young Jeong, Young-Jae Cho, Jung-Joo Choi, Jae Ryoung Hwang, Ju-Yeon Choi, Jason K Sa, Jeong-Won Lee. Gynecol Oncol 2022
0

Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.
Razan Sheta, Magdalena Bachvarova, Marie Plante, Marie-Claude Renaud, Alexandra Sebastianelli, Jean Gregoire, Jamilet Miranda Navarro, Ricardo Bringas Perez, Jean-Yves Masson, Dimcho Bachvarov. J Transl Med 2020
3


Longstocking, LLC. © 2021
Home | About Us | FAQs | Terms & Privacy